20.96
+4.49%
Close of 9 Nov 2026, in BRL
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Fleury
Its shares trade on B3 under the ticker FLRY3.SA. It has been listed since 16 December 2009. In the fiscal year to 31 December 2025, it reported revenue of BRL 8.29bn and net income of BRL 612.8m. At that date it held total assets of BRL 13.22bn and shareholders' equity of BRL 5.00bn.
Fleury SA engaged in the provision of medical diagnostic services. The company is headquartered in Sao Paulo, Sao Paulo. The company went IPO on 2009-12-16. The Company’s activities are divided into three business lines: Patient Service Centers (PSC), B2B and Dental Diagnosis. The PCS division offers private medical diagnostics. The B2B division is responsible for clinical analysis and diagnostic imaging in partner hospitals, as well as tests for laboratories, hospitals and clinics throughout Brazil. The Dental Diagnosis division provides dental diagnostic imaging through Papaiz Associados Diagnosticos por Imagem SA, a joint venture with Odontoprev SA. The firm operates through several brands, such as Fleury Medicina e Saude, Clinica Felippe Mattoso e Weinmann, a+ Medicina Diagnostica, Diagnoson a+, Diagmax and Inlab, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 16 Dec 2009
- Employees
- 16,700
- Website
- fleury.com.br ↗
Leadership
Pay as last reported
- Mr. Marcio MendesChairman of the Board
- Ms. Jeane TsutsuiChief Executive Officer, Member of the Executive Board, since 2021
- Mr. Fernando AlbertoVice Chairman of the Board
- Mr. Jose de Almeida FilippoChief Financial and Investor Relations Officer, Member of the Executive Board
- Ms. Patricia BertoncelloMember of the Executive Board, Service Units Officer
- Mr. Roberto MeirellesMember of the Executive Board, L2L and Operations Support Officer
- Mr. Edgar RizzattiMember of the Executive Board, Medical, Technical and Process Officer, since 2021
- Mr. Luiz CappiDirector
- Mr. Rui de Barros MacielDirector
- Mr. Samuel dos SantosDirector, since 2017
- Mr. Ivan GontijoDirector
- Mr. Marcio de Paula RicardoIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 87
- Environment
- 99
- Social
- 99
- Governance
- 62
- Direct emissions (scope 1)
- 7,918.57 t
- Energy emissions (scope 2)
- 3,755.06 t
- Value chain emissions (scope 3)
- 141,173.84 t
- Women in the workforce
- 79%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Fleury SA has established itself as a leading healthcare provider in Brazil, boasting a strong brand reputation and a wide range of medical services.
- The company has a vast network of hospitals, labs, and clinics, allowing it to serve a large customer base and generate significant revenue.
- Fleury SA's technological capabilities and investment in advanced medical equipment enable them to offer high-quality and accurate diagnostic services.
Weaknesses
- One weakness of Fleury SA is its heavy dependency on the Brazilian healthcare system. Any changes in government policies or regulations can significantly impact the company's operations and profitability.
- The high cost of healthcare services provided by Fleury SA may limit access for some potential customers.
- Fleury SA's expansion plans outside of Brazil are limited, potentially hindering its growth opportunities in international markets.
Opportunities
- With the increasing demand for healthcare services in Brazil, Fleury SA has the opportunity to expand its market share and reach a larger customer base.
- There is a growing trend towards preventive healthcare, which opens up opportunities for Fleury SA to develop and offer new services focused on early detection and disease prevention.
- International expansion into emerging markets could diversify Fleury SA's revenue streams and reduce its reliance on the Brazilian market.
Threats
- Intense competition within the Brazilian healthcare industry poses a threat to Fleury SA's market position and profitability.
- Economic downturns and fluctuations in healthcare spending can negatively impact Fleury SA's revenue and financial performance.
- Changes in healthcare regulations and reimbursement policies can create challenges for Fleury SA in terms of cost control and compliance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.